Navigation Links
Chugai in Medical News

Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...ce is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & J...

ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress

...ates. ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Roche Announces New Co-pay Program in Pennsylvania that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

...e pharmacokinetics and significant reduction in viral load, with good tolerability and safety.(3) Romark recently entered into an agreement granting chugai Pharmaceutical Co., Ltd., a member of the Roche Group, an exclusive license to develop and market nitazoxanide for the treatment of chronic hepatitis ...

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

...lines of biological therapy, and reserve agents with other mechanisms of action, such as Orencia and Biogen Idec/Genentech's Rituxan (also marketed by chugai and Zenyaku Kogyo in Japan, and marketed as MabThera in Europe by Roche), largely for TNF-alpha inadequate responders. According to the new report ent...

Global Growth Factors (Blood and Tissue) Market to Reach $52.1 Billion by 2012, According to New Report by Global Industry Analysts

...rtho Inc, Lonza Group, Maxygen Inc, Merck Serono International SA, NsGene A/S, PeproTech Inc, Rentschler Biotechnologie GmbH, F Hoffmann-La Roche Ltd, chugai Pharmaceutical Co Ltd, Genentech Inc, Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd, among others. The report titled "Growth Fac...

FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...
Chugai in Medical Technology

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

...DA). ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: http://www.roche.com . All trademarks used or mentioned in this release are protected by law. ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

...ates. ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

.... ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

...d States and Europe. ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

...d States and Europe. ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

... the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In April 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, ACTEMRA was approved for the treatment of rheumatoid arthritis, juvenile idiopathic arth...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2006, additional indications for rheumatoid arthritis and systemic-onset juvenile idiopathic a...

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

...bition of structural damage in 2008. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. ACTEMRA was launched in Japan by chugai in June 2005 as a therapy for Castleman's disease. Additional indications for RA and systemic-onset juvenile idiopathic arthritis were also filed in J...
Chugai in Biological Technology

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...

Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better

... Group posted sales of 45.6 billion Swiss francs. Genentech (United States) is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical (Japan). For more information, visit www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected ...

Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer

...nald served as Senior Vice President and Chief Business Officer at Aeterna Zentaris, and, prior to that, Senior Vice President, Business Operations at chugai Pharma USA. At both firms, she had a key role in establishing new directions for the enterprise and facilitating relationships with the financial com...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

...in the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai Pharmaceuticals Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO

...f experience in the pharmaceutical industry, most recently as President and CEO of AEterna Zentaris. Dr. Mazzo also has served as President and CEO of chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group. Dr. Mazzo replaces Regado co- founder D...

Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development

... on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at chugai Pharma USA in San Diego. "We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a h...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...BELLO A/S (OMX Nordic Exchange Copenhagen: ALK.B) chugai PHARM CO (Tokyo SE: 4519) DR REDDYS LABS LTD (NYS...) Add ABRAXIS BIOSCIENCE INC (NASDAQ: ABII ) chugai PHARM CO (Tokyo SE: 4519) DR REDDYS LABS LTD (NYS...N ) CARL ZEISS MEDITEC (Frankfurt, Germany: AFX) chugai PHARM CO (Tokyo SE: 4519) CIGNA CORP (NYSE: CI )...

Leading global Big Pharma companies of 2005

... +21% 30 32 Altana (Germany) $2.8 +27% Source: Pharmaceutical Executive , May 2006 * includes sales from acquisition of Japanese company chugai but does not include sales from majority-owned position in Genentech ** merger of Yamanouchi and Fujisawa to become Astellas *** does not include re...
Other Tags
(Date:7/28/2014)... Reinberg HealthDay Reporter MONDAY, ... and heart rhythm irregularities are more likely to get a ... In fact, the study of more than 16,000 people found ... likely to get a pacemaker than those without the memory-robbing ... why folks with dementia are so much more likely to ...
(Date:7/28/2014)... Dearborn, Michigan (PRWEB) July 28, 2014 ... from Drs. Harris, Birkhill, Wang, Songe and Associates, PC ... generations and countless tomorrows to come. , The ... group, responsible for more than $2.5 million in donations. ... the title sponsors for the Oakwood Women’s Healthcare Classic ...
(Date:7/28/2014)... Amy Norton HealthDay Reporter ... are commonly done to relieve sleep apnea in children, but ... weight gain -- especially if they,re already overweight. The ... factor for a range of health problems -- including, ironically, ... who need it. Instead, they said, doctors and parents ...
(Date:7/28/2014)... July 28, 2014 Lourdes Health System ... access and reduced wait times for veterans needing medical ... systems in the state—and the only one in Camden, ... Patient-Centered Community Care program (PC3). PC3 gives veterans access ... hospital cannot provide services due to lack of available ...
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
Breaking Medicine News(10 mins):Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... Research Hospital study found that 73 percent of adult ... of developing metabolic syndrome and related health problems by ... in the current issue of the journal Cancer ... survivors of childhood cancer in the study had metabolic ... high blood pressure, abdominal obesity, elevated triglyceride and other ...
(Date:7/28/2014)... 2014 Research and Markets has ... Latin America 2014-2018" report to their offering. ... measure and analyze biological data. These systems capture biological ... voice patterns, and hand measurements from the subject and ... The main purpose of a biometrics system is to ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Biometrics Market in Latin America 2014-2018 2
Other Contents